ML290 | CAS#1482500-76-4 |RXFP1 Agonist

MedKoo Cat#: 533244 | Name: ML290

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML290 is a potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1).

Chemical Structure

ML290

CAS#1482500-76-4

Theoretical Analysis

MedKoo Cat#: 533244

Name: ML290

CAS#: 1482500-76-4

Chemical Formula: C24H21F3N2O5S

Exact Mass: 506.1123

Molecular Weight: 506.50

Elemental Analysis: C, 56.91; H, 4.18; F, 11.25; N, 5.53; O, 15.79; S, 6.33

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 Weeks
25mg	USD 850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ML290; ML 290; ML-290.

IUPAC/Chemical Name

2-[(2-propan-2-yloxybenzoyl)amino]-N-[3-(trifluoromethylsulfonyl)phenyl]benzamide

InChi Key

RSYHJSDOGMSLDH-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H21F3N2O5S/c1-15(2)34-21-13-6-4-11-19(21)23(31)29-20-12-5-3-10-18(20)22(30)28-16-8-7-9-17(14-16)35(32,33)24(25,26)27/h3-15H,1-2H3,(H,28,30)(H,29,31)

SMILES Code

O=C(NC1=CC=CC(S(=O)(C(F)(F)F)=O)=C1)C2=CC=CC=C2NC(C3=CC=CC=C3OC(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

ML-290 is a relaxin/insulin-like family peptide receptor (RXFP1) agonist and activator of anti-fibrotic genes, with an EC50 of 94 nM.

In vitro activity:

Therefore, this study has tested the effect of ML290 on primary human HSC gene expression (Figure 3). Cells were cultured on plastic, which induces and maintains activation of HSCs. Upon treatment with 5μM of ML290, this study observed a clear anti-fibrotic, relaxin-like gene expression pattern at 24 and 72 hr. Similar results have been recently reported by another group in the HSC LX-2 cell line using ML-290. Reference: Eur J Med Chem. 2018 Aug 5;156:79-92. https://pubmed.ncbi.nlm.nih.gov/30006176/

In vivo activity:

The pharmacokinetics of ML290 in mice demonstrated its high stability in vivo, as evidenced by the sustained concentrations of compound in the liver. In mice expressing human RXFP1 gene treated with carbon tetrachloride, ML290 significantly reduced collagen content, α-smooth muscle actin expression, and cell proliferation around portal ducts. In conclusion, ML290 demonstrated antifibrotic effects in liver fibrosis. Reference: FASEB J. 2019 Nov;33(11):12435-12446. https://pubmed.ncbi.nlm.nih.gov/31419161/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	59.23
	DMF:PBS (pH 7.2) (1:2)	0.3	0.65
	DMSO	75.0	148.08
	Ethanol	0.1	0.28

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 506.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Wilson KJ, Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Xu X, Wang A, Myhr C, Barnaeva E, George ER, Agoulnik AI, Marugan JJ. Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. Eur J Med Chem. 2018 Aug 5;156:79-92. doi: 10.1016/j.ejmech.2018.06.008. Epub 2018 Jun 7. PMID: 30006176; PMCID: PMC6102074. 2. Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA, Wang C, Hutchinson DS, Samuel CS, Agoulnik AI, Bathgate RAD, Summers RJ. ML290 is a biased allosteric agonist at the relaxin receptor RXFP1. Sci Rep. 2017 Jun 7;7(1):2968. doi: 10.1038/s41598-017-02916-5. PMID: 28592882; PMCID: PMC5462828. 3. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16. PMID: 31419161; PMCID: PMC6988856. 4. Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PMID: 26347712; PMCID: PMC4538381.

In vitro protocol:

In vivo protocol:

1. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. FASEB J. 2019 Nov;33(11):12435-12446. doi: 10.1096/fj.201901046R. Epub 2019 Aug 16. PMID: 31419161; PMCID: PMC6988856. 2. Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PMID: 26347712; PMCID: PMC4538381.

1: Agoulnik AI, Agoulnik IU, Hu X, Marugan J. Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol. 2016 Oct 23. doi: 10.1111/bph.13656. [Epub ahead of print] Review. PubMed PMID: 27771940. 2: Hu X, Myhr C, Huang Z, Xiao J, Barnaeva E, Ho BA, Agoulnik IU, Ferrer M, Marugan JJ, Southall N, Agoulnik AI. Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. Biochemistry. 2016 Mar 29;55(12):1772-83. doi: 10.1021/acs.biochem.5b01195. PubMed PMID: 26866459; PubMed Central PMCID: PMC5137375. 3: Huang Z, Myhr C, Bathgate RA, Ho BA, Bueno A, Hu X, Xiao J, Southall N, Barnaeva E, Agoulnik IU, Marugan JJ, Ferrer M, Agoulnik AI. Activation of Relaxin Family Receptor 1 from Different Mammalian Species by Relaxin Peptide and Small-Molecule Agonist ML290. Front Endocrinol (Lausanne). 2015 Aug 17;6:128. doi: 10.3389/fendo.2015.00128. PubMed PMID: 26347712; PubMed Central PMCID: PMC4538381. 4: Halls ML, Bathgate RA, Sutton SW, Dschietzig TB, Summers RJ. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol Rev. 2015;67(2):389-440. doi: 10.1124/pr.114.009472. Review. PubMed PMID: 25761609; PubMed Central PMCID: PMC4394689. 5: Diepenhorst NA, Petrie EJ, Chen CZ, Wang A, Hossain MA, Bathgate RA, Gooley PR. Investigation of interactions at the extracellular loops of the relaxin family peptide receptor 1 (RXFP1). J Biol Chem. 2014 Dec 12;289(50):34938-52. doi: 10.1074/jbc.M114.600882. PubMed PMID: 25352603; PubMed Central PMCID: PMC4263891. 6: Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer M, Southall N, Hu X, Zheng W, Agoulnik AI, Marugan JJ. Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1). 2012 Mar 10 [updated 2013 May 8]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK153218/ PubMed PMID: 23905199.